 |
39 Products |  |
109 Diseases | | 39 Products |
|
42 Trials |  |
1950 News |  |
| «12345678910111213...2021» |
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Journal: Tivozanib-induced activation of the mitochondrial apoptotic pathway and suppression of epithelial-to-mesenchymal transition in oral squamous cell carcinoma. (Pubmed Central) - Apr 29, 2024
These findings highlight the substantial anticancer potential of tivozanib in OSCC and thus its promise as a therapeutic option. Beyond reducing cell viability and inducing apoptosis, the capacity of tivozanib to inhibit EMT and modulate key proteins presents the possibility of a paradigm shift in OSCC treatment.
- || Review, Journal: Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. (Pubmed Central) - Apr 28, 2024
Other combination therapies include pembrolizumab (targeting programed cell death protein 1) and axitinib (a VEGFR and PDGFR blocker) or lenvatinib (a multikinase inhibitor). Since the KEYNOTE-426 clinical trial, the use of immune checkpoint inhibitors in combination with protein-tyrosine kinase inhibitors is now the standard of care for most patients with metastatic renal cell carcinomas and monotherapies are used only in those individuals who cannot receive or tolerate immune checkpoint inhibitors.
- Keytruda (pembrolizumab) / Merck (MSD), CUE-101 / Cue Biopharma, LG Chem
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). (S100a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3595;
P1
A median OS of 20.8 was observed in patients treated with CUE-101 monotherapy as post-platinum/CPI therapy. CUE-101 continues to demonstrate safety, tolerability and meaningful clinical benefit in patients with HPV16+ R/M HNSCC.
- CUE-102 / Cue Biopharma, LG Chem
A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers. (Hall A; Poster Bd #: 216) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2622;
P1
No DLTs or drug-related SAEs have been observed in doses up to 8 mg/kg as of the data cut-off. Adverse events have been manageable and consistent with the CUE-102 mechanism of action and underlying disease.
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem, Opdivo (nivolumab) / BMS
Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial. (Hall A; Poster Bd #: 304b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1777;
P2
Exploratory analyses with circulating tumor DNA (pre-treatment, cycle 2, and end of treatment), archival tissue, and on-treatment biopsy (cycle 4) are planned to examine the biologic correlates associated with therapy response. Enrollment began in January 2024.
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Preclinical, Journal: Improvement effect of gemigliptin on salivary gland dysfunction in exogenous methylglyoxal-injected rats. (Pubmed Central) - Apr 17, 2024
Overall, gemigliptin protected the salivary gland cells from ROS-mediated cell death, reduced the accumulation of amylase and mucins in the salivary glands, and enhanced the salivary function by upregulating aquaporin 5 expression, and it exerted protective effects against MGO-induced salivary gland dysfunction by enhancing the anti-glycation, antioxidant, and salivary secretion activities. Our findings suggest gemigliptin as a potential therapeutic for patients with salivary gland dysfunction caused by the complications of diabetes.
- | CUE-101 / Cue Biopharma, LG Chem
Trial completion date, Trial primary completion date, Surgery, Metastases: Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma (clinicaltrials.gov) - Apr 16, 2024
P2, N=30, Recruiting, Sponsor: Washington University School of Medicine
Our findings suggest gemigliptin as a potential therapeutic for patients with salivary gland dysfunction caused by the complications of diabetes. Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
- | AV-380 / LG Chem
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Dose Escalation Study of AV-380 in Metastatic Cancer Patients with Cachexia (clinicaltrials.gov) - Apr 4, 2024
P1, N=30, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027 Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Jul 2025
- Besivo (besifovir) / Gilead, LG Chem, Ildong
Comparable outcomes between Besifovir and other antiviral therapies in hepatocellular carcinoma development among patients with chronic hepatitis B (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_828;
BSV showed comparable outcomes in HCC development among patients with CHB compared to TAF, ETV, and TDF. Given the small number of events and the relatively short follow-up duration observed in BSV users, further long-term analysis is warranted.
- | Lantus (insulin glargine) / Sanofi, Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Journal: Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus (Pubmed Central) - Apr 1, 2024
Given the small number of events and the relatively short follow-up duration observed in BSV users, further long-term analysis is warranted. GL Glargine was similar to Lantus
- | TNFcept (etanercept biosimilar) / LG Chem, Mochida
Journal, Real-world evidence, Real-world: Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort. (Pubmed Central) - Mar 22, 2024
GL Glargine was similar to Lantus This real-world cohort study confirmed that the biosimilar of ETN, LBEC0101, was comparable to the reference product in terms of continuation rate, effectiveness at initiation of introduction, and effect persistence before and after switching in clinical practice.
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) - Mar 22, 2024
P1, N=30, Completed, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This real-world cohort study confirmed that the biosimilar of ETN, LBEC0101, was comparable to the reference product in terms of continuation rate, effectiveness at initiation of introduction, and effect persistence before and after switching in clinical practice. Not yet recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
- | Besivo (besifovir) / Gilead, LG Chem, Ildong, Vemlidy (tenofovir alafenamide) / Gilead
Retrospective data, Journal, Head-to-Head: Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Na (Pubmed Central) - Mar 15, 2024
The absolute value of the 95% confidence interval for the difference (-0.04 to 0.12) satisfied the a priori limit of a noninferiority of 0.15. : BSV is noninferior to TAF in terms of VR, and their clinical outcomes are comparable to CHB.
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
Journal: Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy. (Pubmed Central) - Mar 13, 2024
P3
In conclusion, BSV decreased the risk of HCC in patients with CHB, and prediction models were applicable. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806.
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Cost-Effectiveness of Tivozanib in Advanced Renal Cell Carcinoma in the US () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_559;
Tivozanib increased in QALYs at an additional cost compared to sorafenib. At a $150,000/QALY willingness-to-pay threshold, tivozanib was not deemed cost-effective.
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Journal: Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway. (Pubmed Central) - Mar 6, 2024
In conclusion, gemigliptin dose dependently effects the EPCs viability and morphology through Caspase-3 signaling. Our results are the first report of gemigliptin effect on EPC viability and morphology.
- | ICM-203 / Yonsei Technology Holdings
Trial completion date, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (clinicaltrials.gov) - Mar 5, 2024
P1/2, N=18, Not yet recruiting, Sponsor: ICM Co. Ltd.
Our results are the first report of gemigliptin effect on EPC viability and morphology. Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: May 2024 --> May 2025
- pinometostat (EPZ-5676) / Ipsen, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
A systems biology approach for identifying targetable vulnerabilities in Ewing sarcoma (Section 36) - Mar 5, 2024 - Abstract #AACR2024AACR_7569;
Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: May 2024 --> May 2025 These systems biology approaches can identify non-oncogene encoded vulnerabilities in Ewing sarcoma and hold the potential for expanding the number of therapeutic options for tumors driven by untargetable oncoproteins.
- Keytruda (pembrolizumab) / Merck (MSD)
Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC) (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_6655;
These systems biology approaches can identify non-oncogene encoded vulnerabilities in Ewing sarcoma and hold the potential for expanding the number of therapeutic options for tumors driven by untargetable oncoproteins. Abstract is embargoed at this time.
- A cytosolic complex between exportin-7(XPO7) and ste20-like kinase (SLK) regulates PI3K-AKT-mTOR signaling in cholangiocarcinoma (Section 52) - Mar 5, 2024 - Abstract #AACR2024AACR_4750;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- | MIT-001 / MitoImmune Therap
Preclinical, Journal: In vitro broad-spectrum antiviral activity of MIT-001, a mitochondria-targeted reactive oxygen species scavenger, against severe acute respiratory syndrome coronavirus 2 and multiple zoonotic viruses. (Pubmed Central) - Mar 4, 2024
The presence of MIT-001 also alleviated mitochondrial depolarization caused by SARS-CoV-2 infection. These findings highlight the potential of MIT-001 as a broad-spectrum antiviral compound that targets for zoonotic RNA and DNA viruses, providing a promising therapeutic approach to combat viral infection.
- | GEN-001 / Genome & Company
Journal: Profiling of endogenous metabolites and changes in intestinal microbiota distribution after GEN-001 (Lactococcus lactis) administration. (Pubmed Central) - Feb 28, 2024
Compared with predose, the relative abundance (%) of Parabacteroides and Alistipes significantly decreased, whereas that of Lactobacillus and Lactococcus increased; Lactobacillus and tryptophan levels were negatively correlated. A single administration of GEN-001 shifted the gut microbiota in healthy volunteers to a more balanced state as evidenced by an increased abundance of beneficial bacteria, including Lactobacillus, and higher levels of the metabolites that have immunogenic properties.
- || tigulixostat (LC350189) / LG Chem
New P1 trial: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) - Feb 25, 2024
P1, N=30, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- || Fotivda (tivozanib) / Kyowa Kirin, LG Chem, Tecentriq (atezolizumab) / Roche
Enrollment open, Trial completion date, Trial primary completion date: IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov) - Feb 20, 2024
P1/2, N=29, Recruiting, Sponsor: University of Florida
A single administration of GEN-001 shifted the gut microbiota in healthy volunteers to a more balanced state as evidenced by an increased abundance of beneficial bacteria, including Lactobacillus, and higher levels of the metabolites that have immunogenic properties. Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024 | Suspended --> Recruiting
- ||| LR19024 / LG Chem
Enrollment closed, Enrollment change: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA (clinicaltrials.gov) - Feb 9, 2024
P1/2, N=74, Active, not recruiting, Sponsor: LG Chem
Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024 | Suspended --> Recruiting Recruiting --> Active, not recruiting | N=135 --> 74
- || tigulixostat (LC350189) / LG Chem
Clinical, Journal: Comment on serum urate-lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial. (Pubmed Central) - Feb 3, 2024
Recruiting --> Active, not recruiting | N=135 --> 74 No abstract available
- || Shinbaro (GCSB-5) / GC Biopharma, LG Chem
Review, Journal: Efficacy of herbal medicine in hand osteoarthritis: A narrative review. (Pubmed Central) - Jan 30, 2024
However, there is a lack of strong evidence supporting their effectiveness in hand osteoarthritis (HOA). This emphasizes the potential benefits that these herbs may have for HOA patients.
- Keytruda (pembrolizumab) / Merck (MSD), CUE-101 / Cue Biopharma, LG Chem
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3rd line and in combination with pembrolizumab in 1st line recurrent/metastatic (R/M) HPV16+ head and neck cancer patients. (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #7) - Jan 24, 2024 - Abstract #MHNCS2024MHNCS_293;
Patients treated with CUE-101 monotherapy in 3L showed a long OS. CUE-101 and pembrolizumab combination resulted in an ORR of 47% and decrease in HPV16 cfDNA in the 1L treatment of patients with HPV16+ R/M HNSCC.
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC) (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #2) - Jan 24, 2024 - Abstract #MHNCS2024MHNCS_182;
Purpose/Objective(s): For patients with R/M HNSCC, current treatments are palliative with anti-PD-1 checkpoint inhibitor +/- platinum and 5-fluorouracil chemotherapy for first-line followed by taxanes, methotrexate, and cetuximab as later-line options. TBD
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Preclinical, Journal: Gemigliptin Improves Salivary Gland Dysfunction in D-Galactose-Injected Aging Rats. (Pubmed Central) - Jan 23, 2024
In sum, gemigliptin was shown to improve D-gal-induced decline in the salivary gland function of aged rats through its anti-glycation and antioxidant activities. Gemigliptin shows promise as a treatment strategy for patients experiencing decreased salivary function associated with their advancing age.
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Journal: A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study). (Pubmed Central) - Jan 19, 2024
Gemigliptin add-on therapy may be more effective than metformin dose escalation in patients with T2DM insufficiently controlled using metformin and SGLT2 inhibitors, without safety concerns. This trial is registered with CRIS_number: KCT0003520.
- | Retrospective data, Journal, Metastases: Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma. (Pubmed Central) - Jan 12, 2024
Based on OS and PFS, the lenvtatinib?+?everolimus combination yielded superior, followed by cabozantinib and Lenvatinib monotherapies; all were limited by a worse SAE profile. Nivolumab and pazopanib had the lowest odds of SAEs.
- || Fotivda (tivozanib) / Kyowa Kirin, LG Chem, Opdivo (nivolumab) / BMS
Enrollment open, Metastases: FORTUNE: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 9, 2024
P2, N=48, Recruiting, Sponsor: M.D. Anderson Cancer Center
Nivolumab and pazopanib had the lowest odds of SAEs. Not yet recruiting --> Recruiting
- Gemiglo (gemigliptin) / Sanofi, LG Chem
Gemigliptin alleviates succinate induced ER stress and activation of hepatic stellate cells (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_1916;
This study showed the involvement of ER stress in the activation of succinate-induced LX-2 HSCs and gemigliptin significantly reduced ER stress in HSC activation. Therefore, gemigliptin may become an anti-fibrotic agent and targeting to succinate and ER stress may be a promising therapeutic in the management of liver fibrosis.
- ||| Retrospective data, Review, Journal, Adverse events: Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis. (Pubmed Central) - Jan 5, 2024
Higher-potency and lower-selectivity VEGF-TKIs may influence the risks of MACEs, heart failure, and thromboembolism. These findings may facilitate evidence-based decision-making in clinical practice.
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Effect of Tigulixostat on the Pharmacokinetics of Theophylline (clinicaltrials.gov) - Jan 2, 2024
P1, N=24, Completed, Sponsor: LG Chem
- Fotivda (tivozanib) / Kyowa Kirin, LG Chem, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=29, Suspended, Sponsor: University of Florida
- ||||| ficlatuzumab (AV-299) / LG Chem
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: FIERCE-HN: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 31, 2023
P3, N=410, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- || Review, Journal: Pipeline Therapies for Gout. (Pubmed Central) - Dec 22, 2023
A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study...Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC). (Level 1, West Hall; Poster Bd # G22) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_762;
In this cohort of heavily pretreated pts with advanced ccRCC, TIVO yielded a modest clinical benefit in a minority of pts who received prior ICT, CABO, and LEN +/- EVE. TRAEs observed with TIVO were consistent with previously published reports.
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem, Tecentriq (atezolizumab) / Roche
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors. (Level 1, West Hall; Poster Bd # Q18) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_198;
P1/2
Active enrollment continues. Clinical trial information: NCT05000294.
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Journal: The effect of gemigliptin treatment on immune parameters including regulatory T cells in patients with type 2 diabetes and moderate to very severe chronic renal impairment. (Pubmed Central) - Dec 9, 2023
Treatment with gemigliptin for 3 and 6 months did not significantly alter the number, percentage, or ratio of circulating Treg cells in patients with type 2 diabetes and CKD. Therefore, the administration of gemigliptin may help maintain regulatory T cells or have no significant impact.
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem, Tecentriq (atezolizumab) / Roche
A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies. (Poster Bd # Q4) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_373;
P1/2
Treatment will continue until progression or intolerance. Clinical trial information: NCT05000294.
- Bavencio (avelumab) / EMD Serono, GEN-001 / Genome & Company
Phase II study of GEN-001 in combination with avelumab in patients with PD-L1 (Poster Bd # H10) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_251;
P2
The results from this trial will be updated about its effects on clinical outcome, including survival, safety, and biomarker findings. Clinical trial information: NCT05419362.
- ||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem, Opdivo (nivolumab) / BMS
Enrollment change, Metastases: FORTUNE: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 30, 2023
P2, N=48, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Clinical trial information: NCT05419362. N=10 --> 48
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Journal: Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy. (Pubmed Central) - Nov 28, 2023
N=10 --> 48 Collectively, these results suggest that gemigliptin ameliorated NASH via AMPK-independent, ULK1-mediated effects on autophagy.
- |||||| ficlatuzumab (AV-299) / LG Chem
Enrollment open, Combination therapy, Metastases: FIERCE-HN: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 18, 2023
P3, N=410, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Collectively, these results suggest that gemigliptin ameliorated NASH via AMPK-independent, ULK1-mediated effects on autophagy. Not yet recruiting --> Recruiting
- | Shinbaro (GCSB-5) / GC Biopharma, LG Chem
Preclinical, Journal: Shinbaro2 enhances axonal extension beyond the glial scar for functional recovery in rats with contusive spinal cord injury. (Pubmed Central) - Nov 15, 2023
Furthermore, Sh2 promoted the sprouting of serotonergic axons and the growth of neurofibrillary tangles, enhancing motor function recovery in SCI. These findings highlight the potential of Sh2 as an SCI therapeutic intervention, offering hope for neural and functional restoration in individuals with this debilitating condition.
- | Fotivda (tivozanib) / Kyowa Kirin, LG Chem
Phase classification: Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (clinicaltrials.gov) - Nov 13, 2023
P1/2, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
These findings highlight the potential of Sh2 as an SCI therapeutic intervention, offering hope for neural and functional restoration in individuals with this debilitating condition. Phase classification: P2 --> P1/2
- || Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz, Prandilin (insulin lispro biosimilar) / Gan & Lee Pharma, Sandoz, Rapilin (Gan & Lee Insulin Aspart biosimilar) / Gan & Lee Pharma, Sandoz
Clinical, PK/PD data, Journal: Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin (Pubmed Central) - Nov 13, 2023
Phase classification: P2 --> P1/2 GL-Asp, GL-Lis and GL-Gla are bioequivalent to their EU- and US-reference products.